FDA grants ODD to Tempest’s hepatocellular carcinoma treatment
"FDA grants ODD to Tempest’s hepatocellular carcinoma treatment" was originally created and published by Pharmaceutical ...
Too Old to Operate1h
Nomograms for Predicting Postoperative Outcomes in HCC With CSPH After Resection
The following is a summary of “Development models to predict complication and prognosis following liver resection for ...
NAYA Biosciences Announces Development of NY-500, a Novel AI-Optimized PD-1 x VEGF Bifunctional Antibody
PD-1 x VEGF antibodies show potential to surpass checkpoint inhibitors as standard-of-care in multiple oncology indications• NAYA aiming to ...
Is Your Diet Killing Your DNA? Scientists Uncover Liver Cancer “Ticking Time Bomb”
Liver cells attempt to shut down as a defense mechanism against cancer, but this strategy is not particularly effective.
Pharmaceutical Technology1d
Muzastotug by Adagene Suzhou for Hepatocellular Carcinoma: Likelihood of Approval
Muzastotug is under clinical development by Adagene Suzhou and currently in Phase II for Hepatocellular Carcinoma.
News Medical on MSN8d
Investigating fatty acid metabolism in hepatocellular carcinoma patients
Announcing a new publication for Acta Materia Medica journal. Fatty acid (FA) reprogramming has a significant role in liver cancer. However, the contribution of FA metabolism reprogramming to the ...